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Abstract: Myxoma virus (MYXV) is a Leporipoxvirus that possesses a specific rabbit-restricted host
tropism but exhibits a much broader cellular host range in cultured cells. MYXV is able to efficiently
block all aspects of the type I interferon (IFN)-induced antiviral state in rabbit cells, partially in human
cells and very poorly in mouse cells. The mechanism(s) of this species-specific inhibition of type I
IFN-induced antiviral state is not well understood. Here we demonstrate that MYXV encoded protein
M029, a truncated relative of the vaccinia virus (VACV) E3 double-stranded RNA (dsRNA) binding
protein that inhibits protein kinase R (PKR), can also antagonize the type I IFN-induced antiviral
state in a highly species-specific manner. In cells pre-treated with type I IFN prior to infection, MYXV
exploits M029 to overcome the induced antiviral state completely in rabbit cells, partially in human
cells, but not at all in mouse cells. However, in cells pre-infected with MYXV, IFN-induced signaling is
fully inhibited even in the absence of M029 in cells from all three species, suggesting that other MYXV
protein(s) apart from M029 block IFN signaling in a species-independent manner. We also show that
the antiviral state induced in rabbit, human or mouse cells by type I IFN can inhibit M029-knockout
MYXV even when PKR is genetically knocked-out, suggesting that M029 targets other host proteins
for this antiviral state inhibition. Thus, the MYXV dsRNA binding protein M029 not only antagonizes
PKR from multiple species but also blocks the type I IFN antiviral state independently of PKR in a
highly species-specific fashion.
Keywords: Myxoma virus; M029; Poxvirus; type I IFNs, antiviral state; dsRNA binding protein; PKR
1. Introduction
Evasion of host innate immune responses is one of the key steps for successful replication and
pathogenesis for all viruses that infect vertebrate hosts. Type I interferons (IFNs) play a central role
in inducing early antiviral responses to combat most virus infections [1,2]. The synthesis of type I
IFN ligands is initiated upon innate sensing of viruses and their virus-induced pathogen-associated
molecular patterns (PAMPs) by cellular pattern recognition receptors (PRRs). Activation of PRRs
induces signaling cascades that lead to the rapid expression of genes encoding antiviral cytokines, such
as the type I IFNs. Induced IFNs are then secreted and bind their cognate receptors on either the same
virus-infected cells (autocrine stimulation) or on neighboring uninfected cells (paracrine stimulation)
to initiate the IFN signaling cascade that leads to the formation of a transcriptional activation complex
called ISGF3, which finally upregulates a large suite of IFN-stimulated genes (ISGs). The summated
activities of many dozens or even hundreds of induced ISGs then operationally mediate the antiviral
state that limits the progression of the virus infection. However, the capacity of the IFN-induced
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antiviral state to block any given virus varies greatly depending on not only the virus anti-IFN
strategies, but also the cell type and species of the infected host.
Large DNA viruses like poxviruses inhibit these IFN-dependent antiviral responses at multiple
levels. Like many poxviruses, Myxoma virus (MYXV), a member of the Leporipoxvirus genus, exhibits
a very restricted host range in nature within the lagomorph family and is totally nonpathogenic in
hosts outside rabbit species [3,4]. In European rabbits (O. cuniculis), MYXV causes a unique lethal
disease called myxomatosis, in which essentially all of the host innate and acquired immune pathways
are rendered ineffectual. However, in contrast, MYXV exhibits a much broader cellular tropism for
cultured transformed cell lines derived from many diverse mammalian species outside the rabbit [5].
Antiviral cytokines, such as tumor necrosis factor (TNF) or Type I IFN, are known to play significant roles
in the restriction of MYXV replication in primary cells from non-rabbit hosts [6]. For example, primary
mouse fibroblasts are nonpermissive for MYXV replication because of the rapid induction of type I IFN
in response to MYXV infection, which then mediates an antiviral state that the virus cannot overcome [7].
The critical role of type I IFN in protection against MYXV infection in mice was further confirmed by the
observation that mice lacking signal transducer and activator of transcription 1 (STAT1) are susceptible to
lethal MYXV infection after intracranial inoculation [7]. On the other hand, primary human fibroblasts
are permissive to MYXV replication and do not induce IFN as a consequence of the infection, but these
cells can be induced to become nonpermissive after pre-treatment with type I IFN and/or TNF [6,8].
Interestingly, primary human macrophages are nonpermissive for MYXV because these cells do induce
type I IFN as a consequence of retinoic acid-inducible gene I (RIG-I) sensing of the MYXV infection [9].
Since MYXV is currently being developed as oncolytic virus for many classes of human cancers, a
more detailed understanding of how MYXV responds to IFN activities in different host species and in
cell types of varying lineages will help to provide more mechanistic explanations for why the virus is
utterly rabbit-specific in nature, but also possesses an apparently expanded tropism for cancer cells
and tissues in mice and humans [10–12].
Poxviruses encode dozens of proteins that have evolved to counteract the various host innate
antiviral immune responses, such as those induced by the type I IFNs [13,14]. For example, multiple
vaccinia virus (VACV) proteins have been identified that antagonize IFN responses at many levels,
such as minimizing the sensing of viral PAMPs, neutralizing the IFN ligands by preventing their
binding to IFN receptors, blocking the Janus kinase/signal transducer and activator of transcription
(JAK/STAT) signal transduction pathway after IFN receptor activation, and finally the more global
inhibition of elements of the antiviral state induced by multiple ISGs [15,16]. For example, three
of the known vaccinia virus host range genes, namely E3L, K1L and C7L also antagonize antiviral
activities induced by type I IFNs. VACV lacking expression of E3L or both K1L and C7L are defective
for replication in many mammalian cell lines [17,18]. Mechanistically, K1L and C7L antagonize the
antiviral activities induced by IFN-regulated factor (IRF) 1 [19]. Interestingly, C7L orthologs from many
other poxviruses are able to rescue deletions of VACV C7L. In some cases, a single viral protein may
possess anti-IFN activities at multiple levels. For example, the VACV double-stranded RNA (dsRNA)
binding protein E3 blocks the activation of both IRF3 and IRF7 [20], nuclear factor κB (NF-κB) [21,22]
and ISG15 [23], all of which contribute to the antiviral state after IFN treatment. Thus, deletion of
the E3 gene of VACV results in increased sensitivity to the inhibitory effects of IFNs [24]. However,
the in vitro and in vivo roles of E3 and related dsRNA binding proteins from other pathogens differ
significantly. For example, replacing E3 with dsRNA binding proteins from unrelated viruses or
bacteria or even from other poxviruses can only restore some host range functions of E3 in cell culture
but not in vivo pathogenesis [25]. This suggests that dsRNA-binding or E3-like proteins have acquired
unique host specific immune modulatory functions, depending on their evolutionary origins.
We recently reported that MYXV-encoded dsRNA binding protein, M029—a truncated relative of
VACV E3-like proteins—plays a key role for permissive MYXV replication in essentially all mammalian
cells tested in culture, as well as functions as a critical virulence factor for myxomatosis in European
rabbits [26]. M029 lacks the significant portion of the N-terminal “Z-DNA binding domain” of the
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VACV E3 protein, which is required by VACV for the inhibition of the type I IFN response in mice and in
mouse embryo fibroblasts (MEFs) [27]. At the molecular level, M029 binds and inhibits cellular protein
kinase R (PKR) in a dsRNA-dependent manner in order to subvert PKR-dependent antiviral responses,
even in mammalian cells derived from multiple non-rabbit species, including humans and mice [26].
In addition to PKR as a host cell target, M029 also interacts with another innate cellular protein called
RHA/DHX9, a member of the DEXD/H box family of helicases, in a dsRNA-independent manner to
promote MYXV replication in human cells [26]. Since dsRNA binding proteins have been shown to have
role in the inhibition of host innate responses against viruses, we proposed that M029 will play a key role
against cellular IFN responses. The inhibition of type I IFN responses by VACV E3 is mediated by the
blockade of PKR activation [21]. However, unlike VACV, the cellular tropism for MYXV in human or
mouse cells can be dramatically affected by the extent of induced type I IFN responses [6,8]. A recent
study demonstrated that replacing VACV E3 with MYXV M029 rescues only some of the in vitro functions
of E3 but not the in vivo pathogenesis, which suggests that these two related viral proteins might in fact
possess distinct cellular targets for the modulation of antiviral innate immune responses [25].
In this study, we now demonstrate that M029 plays a major role in the species-specific inhibition
of type I IFN-induced antiviral state against MYXV. MYXV successfully antagonizes essentially all of
the rabbit IFN pathways in rabbit cells, and M029 is critical for counteracting the IFN-induced antiviral
state. However, M029 only partially antagonizes the human type I IFN antiviral state in human cells
and is totally unable to antagonize the murine type I IFN antiviral state in mouse cells. In contrast,
in pre-infected cells from all three species, MYXV is able to effectively inhibit type I IFN-induced
signaling downstream of IFN receptor activation in a fashion that is independent of M029. Importantly,
MYXV sensitivity to type I IFN-induced antiviral state in human and mouse cells cannot be rescued
even in the absence of PKR. These results demonstrate that the MYXV dsRNA binding protein M029
blocks IFN-induced antiviral pathways and also mediates species-specific permissiveness in cells, but
via both PKR-dependent and –independent pathways. M029 effectively inhibits PKR in cells from
multiple species, and thus contributes to the permissive replication of MYXV in many classes of human
cancer cells. In addition, M029 also antagonizes the type I IFN-induced antiviral state independently
of PKR, but in a highly rabbit-specific fashion, this at least partially accounts for the inability of this
virus to infect primary cells and tissues from non-rabbit hosts.
2. Materials and Methods
2.1. Cell Lines and Cell Culture
Rabbit cell line RK13 (ATCC# CCL-37), RK13 expressing VACV E3 protein (RK13-E3; [26], human cell
lines HeLa (ATCC# CCL-2), HeLashControl and HeLashPKR [26], primary human fibroblasts GM02504
(Coriell Institute for Medical Research, Camden, NJ, USA), mouse embryonic fibroblast cell lines NIH3T3
(ATCC# CRL-1658), monkey cell line BSC-40 (ATCC# CRL-2761) all were cultured in Dulbecco minimum
essential medium (DMEM; GIBCO, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with
10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, Georgia, USA), 2 mM glutamine (Invitrogen,
Thermo Fisher Scientific) and 100 µg of penicillin-streptomycin/mL (GIBCO). WT-MEF and MEF PKR-/-
cells (donated by Dr. Robert Silverman of Lerner Research Institute, Cleveland, Ohio, USA) were cultured
in RPMI 1640 medium (BioWhittaker, Lonza, Basel, Switzerland) supplemented with 10% FBS, and 100
µg of pen/strep per mL. All cultures were maintained at 37 ◦C in a humidified 5% incubator. Transfection
of PKR siRNA (Santa Cruz Biotechnology, Dallas, Texas, USA) in RK13 cell line using Lipofectamine
RNAiMAX (Invitrogen) was performed as described before [26].
2.2. Construction of Recombinant Viruses and Viral Preparation
Construction of wild-type (WT)-MYXVs expressing different reporter proteins vMyx-GFP
(WT-MYXV expressing GFP under a poxvirus synthetic early/late promoter), vMyx-Fluc (WT-MYXV
expressing the firefly luciferase protein (Fluc) under a poxvirus synthetic early/late promoter) and
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vMyx-GFP-TdTomato (WT-MYXV expressing GFP under a poxvirus synthetic early/late promoter
and TdTomato under a poxvirus p11 late promoter) were described before [6,28,29]. Construction of
vMyx-M029KO virus was described previously [26,30]. Vesicular stomatitis virus (VSV) expressing GFP
was prepared as described before [31]. A recombination plasmid having reporter genes for Fluc driven
by a synthetic early/late (sE/L) poxvirus promoter and tandem-dimer tomato red fluorescent protein
(Tr-FP) driven by poxvirus p11 late promoter flanked by M135 and M136 gene locus [29] of MYXV was
used to make the vMyx-M029KO-Fluc virus. Briefly, RK13-E3 cells were infected with the vMyx-M029KO
virus for one hour and then the cells were transfected with the recombination plasmids. Multiple rounds
of foci purifications were performed on the same cell lines based on TdTomato-Red and GFP expression
and continued until pure foci were isolated. Recombination was confirmed by polymerase chain reaction
(PCR) using appropriate primers (data not shown). The M029-minus viruses were grown and amplified
in RK13-E3 cells. All other myxoma viruses were grown in BSC40 or RK13 cells.
2.3. Interferon (IFN) Sensitivity and Virus Replication Assays
Cells were seeded in multiwell dishes the day before infection with 60%–70% confluency.
The following day cells were treated individually with hIFNβ/mIFNβ/uIFNα (PBL Assay Science,
Piscataway, NJ, USA; 500 U/mL) or rabbit IFN containing media [26] for 18 h and then infected with
the viruses with different multiplicity of infection (MOI) depending on the experiments. One hour
post-infection (hpi), the media were removed, washed and incubated with fresh medium containing
no or same concentration of IFN that was added. For post-IFN treatment, the cells were first infected
with the viruses for one or six hours (h), the media were removed, washed and incubated with the IFN
containing media. For microscopy, at 24 or 48 hpi, the infected cells were visualized under an inverted
fluorescence microscope and photographed with a digital camera. For viral replication assays, cells
were harvested at various times post-infection and stored in −80 ◦C until processed. Before titration
cells were freeze-thawed at −80 ◦C and 37 ◦C for three times and sonicated for one minute to release
the viruses from infected cells. Depending on the viruses, they were tittered back either RK13 or
RK13-E3 cells by serial dilution.
2.4. Luciferase Assay
Fluc activity was measured to monitor viral gene expression in different cell lines under different
treatment conditions. The assay was performed using 96-well plate. The cells were seeded with
80%–100% confluency and allowed to adhere for overnight or 6–8 h after seeding. For pretreatment
with IFN the complete media was replaced with media containing IFNs (500 U/mL) and incubated for
18 h. For virus infections, viruses were added directly in the media in the presence or absence of IFN
based on the MOI to be used and allowed the infection for different time periods. Luciferase assay
was performed using the luciferase reporter assay kit (Promega, Madison, WI, USA), following
manufacturer instructions. Briefly, media was removed at the indicated time points, cells were washed
with phosphate buffered saline (PBS) once and added the lysis buffer. Lysis was done at RT for
15–20 mins and substrate was added and reading was taken immediately after adding the substrate
using a microplate reader, Appliskan (Thermo Fisher Scientific).
2.5. RNA Purification and Real-Time Polymerase Chain Reaction (qPCR)
For isolation of RNA, 1 × 106 cells were plated in each well of six-well dishes. The following day
cells were mock treated, treated with IFNs or infected with the viruses at a MOI of 5. For post-IFN, cells
were first infected with the viruses for six hours and the media was replaced with IFN containing fresh
media. In all cases cells were harvested 24 h after infection or treatment with IFNs. Total RNA isolation,
cDNA preparation and real-time PCR (qPCR) were performed based on the protocol described
before [6]. The PCR reactions were run on an ABI 7300 qPCR machine under the following conditions:
95 ◦C for 10 min, followed by 40 cycles of 95 ◦C for 15 s and 60 ◦C for 1 min. Primers used for qPCR
analysis are: human GAPDH (F: GTGGACCTGACCTGCCGTCT, R: GGAGGAGTGGGTGTCGCTGT),
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human ISG15 (F: CGCAGATCACCCAGAAGATCG, R: TTCGTCGCATTTGTCCACCA) human Mx1
(F: CAGCACCTGATGGCCTATCA, R: ACGTCTGGAGCATGAAGAACTG), mouse GAPDH (F: AG
GTCGGTGTGAACGGATTTG, R: TGTAGACCATGTAGTTGAGGTCA), mouse ISG15 (F: GGTGT
CCGTGACTAACTCCAT, R: TGGAAAGGGTAAGACCGTCCT), mouse Mx1 (F: GACTACCACT
GAGATGACCCAGC, R: ATTTCCTCCCCAAATGTTTTCA), rabbit GAPDH (F: GTGGACCTGA
CCTGCCGCCT, R: AGAGGAGTGGGTGGCACTGT), rabbit Mx1 (F: CTCATCAGCCTGGAGGTCAG,
R: CCTGATGAGCGCCTTGATCT), rabbit OAS1 (F: TCCGGTTCCTCTGCATCTAC, R: GCCTTGAGC
TGTTTCCTGAC). Amplification of genes was normalized to GAPDH amplification from the same
sample and the fold induction of genes after viral infection or IFN treatment was calculated relative to
the unstimulated control of the cell line.
2.6. Western Blot Analysis
Western blot analysis was performed as described before [26]. Briefly, the mock or virus infected
cells were collected at different time points after infection, washed with PBS and processed with RIPA
lysis buffer. Equal amounts of total proteins were used for Western blot analysis. The membranes were
first probed with primary antibody, washed, incubated with secondary antibody, again washed and
detected using the chemiluminescence substrate and exposure to X-ray film. The detection antibodies
were as follows: rabbit antibodies against phospho-STAT1 and rabbit polyclonal antibodies against STAT1
(Cell Signaling Technology, Danvers, MA, USA); mouse monoclonal antibodies against actin (Ambion,
Thermo Fisher Scientific); mouse monoclonal antibodies against PKR (Santa Cruz Biotechnology);
rabbit antibodies against ISG15 (Cell Signaling Technology). Generation of rabbit polyclonal and mouse
monoclonal antibodies against MYXV proteins M-T7 and Serp-1 was described before [32,33].
2.7. Generation of Knockout Cells Using CRISPR/Cas9
HeLa cells with an inactivated PKR gene were generated by using the CRISPR/Cas9 plasmid
(Santa Cruz Biotechnology) according to the manufacturer’s instructions. After transfection, cells
were treated with puromycin (2 µg/mL) for 48 h. The surviving cells were plated in 96-well plates
with ~1–5 cells/well. Colonies were expanded and were selected according to their ability to support
replication of vMyxM029KO virus.
2.8. Statistical Analysis
Data were expressed as means ± SD and were analyzed by paired t-test. Significant difference
was accepted at p < 0.05.
3. Results
3.1. Species-Specific Inhibition of Type I IFN-Induced Antiviral States by Myxoma Virus (MYXV)
The type I IFN-induced antiviral states in cells originated from different species can have
differential effects on the productive replication of MYXV. In order to examine whether MYXV is able
to overcome the antiviral states in the Type I IFN treated cells, representative species specific cell lines
RK13, GM02504/HeLa and MEF derived from rabbit, human and mouse, respectively were tested.
RK13 cells were pretreated with universal IFNα (uIFNα), human IFNβ (hIFNβ) or rabbit IFN (rIFN)
for 18 h and then infected with the GFP-tagged wild type (WT) MYXV, vMyx-GFP, at an MOI of 0.01
for monitoring virus spread via foci formation or an MOI of 5 for checking single-cycle progeny virus
formation. In RK13 cells, treatment with any of these type I IFNs completely blocked the replication
of control VSV virus, suggesting that antiviral states induced by these type I IFNs are functional
(Figure 1A). However, unlike VSV, the WT-MYXV was able to replicate and form foci normally in
the presence of any of these type I IFNs (Figure 1B). When checked for progeny virus formation at
24 and 48 hpi, the WT-MYXV in the type I IFN treated cells, was also able to produce similar levels
of progeny just like infection without any IFN treatment (Figure 1C). This was further confirmed by
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calculating the log10 changes in virus titers (Figure 1H, top row), where any changes of less than 0.6 log
is regarded as marginal. These results indicate that in rabbit RK13 cells, MYXV is able to inhibit all
aspects of the type I IFN-induced antiviral state to allow permissive virus replication.
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Figure 1. Myxoma virus (MYXV) is able to inhibit the type I interferon (IFN)-induced antiviral
state completely n rabbit cells, partially in huma cells and poorly in mouse cells. RK13 cells
were individually treated with uIFNα, hIFNβ or rIFN containing media for 18 h and (A) infected
with vesicular stomatitis virus (VSV)-GFP at a multiplicity of infection (MOI) of 1.0, fluorescence
images were taken 48 h post-infection (hpi) and a representative image is shown; scale bars (100 µm);
(B) infected with the wild-type (WT)-MYXV at an MOI of 0.01 and fluorescence images were taken
48 hpi; (C) infected with the wild-type (WT)-MYXV at an MOI of 5.0 and then cells were collected at
1 h (adsorption), 24 h and 48 hpi for virus titration; (D) Human GM02504 primary fibroblasts or HeLa
cells were treated with uIFNα or hIFNβ containing media for 18 h and infected with the WT-MYXV at
an MOI of 0.01 and fluorescence images were taken 48 h after infection; (E) GM02504 cells were mock
or treated with uIFNα or hIFNβ containing media for 18 h and infected with the WT-MYXV at an MOI
of 5.0 and then cells were collected at 1 h (adsorption), 24 h and 48 h after infection for virus titration;
(F) Mouse embryo fibroblast (MEF) cells were treated with uIFNα or mIFNβ containing media for
18 h and infected with the WT-MYXV at an MOI of 1.0 and fluorescence images were taken 48 h after
infection; (G) MEF cells were mock or treated with uIFNα or mIFNβ containing media for 18 h and
infected with the WT-MYXV at an MOI of 5.0 and then cells were collected at 1 h (adsorption), 24 h
and 48 hpi for virus titration. The virus titers were determined in triplicate following serial dilution
onto RK13 cells. Statistics are relative to untreated virus titer after 24 h or 48 h infection. ** p < 0.01
*** p < 0.001; (H) Table showing log10 changes in virus titer after different type I IFN treatment compare
to the untreated samples at 24 h and 48 h in RK13, GM02504 and MEFs.
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We then checked whether in human and mouse cell lines, the type I IFN treatment-induced
antiviral states can be overcome by MYXV like in rabbit RK13 cells. Human primary fibroblasts
GM02504 or transformed HeLa cell lines were pretreated with uIFNα or hIFNβ for 18 h and infected
with WT-MYXV at an MOI of 0.01 for foci formation or MOI of 5 for progeny virus formation.
Pre-treatment with either uIFNα or hIFNβ retarded, but did not completely inhibit, the virus spread
and foci formation in both GM02504 and HeLa cells (Figure 1D). As expected, the formation of
progeny virus was also significantly reduced but not completely inhibited under these treatment
conditions in the tested human cell lines, suggesting that MYXV is partially able to inhibit the type I
IFN treatment-induced antiviral state in human cells (Figure 1E). When we calculated log10 changes in
virus titer in response to IFN pre-treatment of human GM02504 cells, hIFNβ reduced virus titer slightly
more than uIFNα but both can be considered to be effective inhibitors of MYXV (Figure 1H, middle
row). Similar to rabbit and human cell lines, immortalized MEFs were pretreated with uIFNα or mIFNβ
for 18 h and infected with WT-MYXV for monitoring infection and progeny virus formation. In MEFs,
although both the type I IFNs reduced MYXV gene expression and replication, pretreatment with
mIFNβ completely inhibited progeny virus formation, unlike the human or rabbit cells (Figure 1F,G).
This was further confirmed by comparing the log10 changes in virus titer after type I IFN treatments
(Figure 1H, lower row).
3.2. M029 is Required for the Global Inhibition of Type I IFN-Induced Antiviral States in Rabbit Cells
Virus-encoded dsRNA-binding proteins, for example VACV E3, are known to antagonize multiple
aspects of IFN-induced activities in infected cells [15]. Based on our observation that MYXV can inhibit
type I IFN-induced antiviral states, but only in a highly species-specific manner, we anticipated that
M029 might have a key role in the inhibition of IFN activities in rabbit cells. To test whether M029
is critical for the inhibition of IFN activities in rabbit cells, RK13 cells were pretreated with uIFNα,
hIFNβ and rIFN for 18 h, and infected with the M029-minus virus, vMyxM029KO, in the continued
presence of type I IFNs. Viral gene expression and foci formation was monitored using fluorescence
microscopy after 48 hpi. Results indicated that vMyxM029KO virus was unable to replicate and form
foci in the presence of any of the type I IFNs in RK13 cells (Figure 2A). This suggests that in rabbit cells
M029 is required by MYXV to antagonize the type I IFN-induced antiviral state and for the subsequent
establishment and spread of virus infection in neighboring cells. We also checked progeny virus
formation at 24 h and 48 hpi with an MOI of 5. The results indicate that in the absence of M029, MYXV
is unable to produce any significant levels of infectious progeny in the presence of hIFNβ or rIFN
(Figure 2B). Under these treatment conditions, uIFNα also reduced the viral titer significantly in RK13
cells, albeit not as efficiently as the other IFNs, which was further evident after calculating the log10
changes in viral titer (Figure 2C). These results further indicate that M029 is required for the inhibition
of the type I IFN-induced antiviral state in rabbit cells.
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were unable to produce any progeny when the cells were treated with mIFNβ prior to virus infection, 
although uIFNα had  less  inhibitory effects on progeny virus  formation  from both  the viruses, as 
observed with other cell lines. This was also supported when we calculated the log10 changes in virus 
titer  for both  the viruses after  treatment with  either uIFNα or mIFNβ  (Figure  3C). These  results 
confirm  that M029  is not capable of antagonizing  the mouse  type  I  IFN‐induced antiviral state  in 
mouse cells but is still required for the inhibition of murine PKR to allow viral replication and cellular 
tropism when IFN is absent. 
i r . 029 is required for the complete inhibition f the type I IFN-induce antiviral state in rabbit
RK13 cells. (A) RK13 cells were treated with uIFNα, hIFNβ or rIFN containing media for 18 h and
infected with the vMyx 029KO virus at an MOI of 0.1 and fluorescence images were taken 48 hpi;
(B) RK13 cells were mock or treated with uIFNα, hIF β or rIFN containing media for 18 h and infected
with the vMyxM029KO virus at an MOI of 5.0 and then cells were collected at 1 h (adsorption), 24 h and
48 hpi for virus titration. The virus titers were determined in triplicate following serial dilution onto
permissive RK13-E3 cells. Statistics are relative to untreated virus titer after 24 h or 48 hpi. ** p < 0.01
*** p < 0.001; (C) Table showing log10 changes in virus titer after different type I IFN treatment compare
to the untreated samples at 24 h and 48 h in RK13.
. . f i i - i li i i
Fibroblasts (MEFs) but Is Unable to Rescue Virus Resistance to the Mouse Type I IFN-Induced Antiviral State
Since M029-minus MYXV, vMyxM029KO, was unable to replicate in WT-MEFs or NIH3T3 murine
cell lines [26], we tested vMyxM029KO virus replication in an engineered PKR-minus MEF cell line
(MEF PKR-/-). The absence of PKR now partially rescued infection and replication of vMyxM029KO
virus in these MEF PKR-/- cells, suggesting that M029 is competent for the inhibition of PKR even
in mouse cells (Figure 3A). When MEF PKR-/- cells were pre-treated with uIFNα or mIFNβ, both
WT-MYXV and M029-minus virus gene expression and infections were blocked to comparable degrees
(Figure 3B). In the MEF PKR-/- cells both WT-MYXV and vMyxM029KO viruses were unable to
produce any progeny when the cells were treated with mIFNβ prior to virus infection, although uIFNα
had less inhibitory effects on progeny virus formation from both the viruses, as observed with other
cell lines. This was also supported when we calculated the log10 changes in virus titer for both the
viruses after treatment with either uIFNα or mIFNβ (Figure 3C). These results confirm that M029 is
not capable of antagonizing the mouse type I IFN-induced antiviral state in mouse cells but is still
required for the inhibition of murine PKR to allow viral replication and cellular tropism when IFN
is absent.
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treatment compare to the untreated samples at 24 h and 48 h in MEF PKR‐/‐ cells. 
3.4. M029 is Required for the Partial Inhibition of Type I IFN‐Induced Antiviral States in Human Cells in 
Either the Presence or Absence of PKR 
MYXV can only partially inhibit human type I IFN activities in IFN‐sensitive human cells. We 
next checked whether M029 played any role in this partial inhibition of type I IFN‐induced antiviral 
state and whether PKR is involved in mediating this IFN‐mediated antiviral activity against MYXV. 
We previously showed that M029‐minus MYXV was able to replicate in human cells only when PKR 
level was reduced [26]. Since  type  I  IFN  treatment  itself can stimulate PKR expression, even with 
shRNA‐mediated PKR knockdown  (data not shown), we have constructed PKR‐knockout human 
HeLa cell lines using CRISPR technology, which respond to exogenous type I IFN, like the human 
fibroblasts cell line GM02504. We selected HeLa PKR‐KO clones that did not express PKR before or 
Figure 3. Loss of protein kinase ( R) can rescue M029-minus MYXV replication in mouse cells
but not overcome sensitivity to the mouse type I IFN-induced antiviral state. (A) MEF PKR-/- cells
were treated with uIFNα, or mIFNβ containing media for 18 h and infected with the WT-MYXV or
vMyxM029KO virus at an MOI of 0.1 and fluorescence images were taken 48 hpi; (B) MEF PKR-/- cells
were mock or treated with uIFNα or mIFNβ containing media for 18 h and infected with the WT-MYXV
or vMyxM029KO viruses at an MOI of 5.0 and then cells were collected at 1 h (adsorption), 24 h and
48 hpi for virus titration. The virus titers were determined in triplicate following serial dilution onto
permissive RK13-E3 cells. Statistics are relative to virus titer after 24 h or 48 h infection. ** p < 0.01
*** p < 0.001; (C) Table showing log10 changes in virus titer after different type I IFN treatment compare
to the untreated samples at 24 h and 48 h in MEF PKR-/- cells.
3.4. M029 is Required for the Partial Inhibition of Type I IFN-Induced Antiviral States in Human Cells in
Either the Presence or Absence of PKR
MYXV can only partially inhibit human type I IFN activities in IFN-sensitive human cells. We next
checked whet er M029 played any role in this partial inhibition of type I IFN-induced antiviral
state and whether PKR is involved in mediating thi IFN-mediated a tivir l activity against MYXV.
We previou ly showed that M029-minus MYXV was able to replicate in human c ll ly when PKR
level was reduced [26]. Si ce type I IFN trea ment itself can stimulate PKR expression, even with
shRNA-m diat d PKR knockdown (data not shown), we have co structed PKR-knockout human
HeLa cell lines using CRISPR technology, which respond to exogenous type I IFN, like the human
fibroblasts cell line GM02504. We selected HeLa PKR-KO clones that did not express PKR before
or after IFN treatment, however, expression of ISG15 was confirmed in these cells, indicating that
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type I IFN responses are still functional (Figure 4A). In these HeLa clones, the partially rescued
replication of vMyxM029KO virus was also confirmed (Figure 4B). Analysis of virus replication using
single step growth curves in HeLa PKR-/- and HeLa control cell lines, demonstrated that the titer of
vMyxM029KO virus was significantly enhanced after PKR knockout (Figure 4C).
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(A) Generation of PKR knockout cells by CRISPR/CAS9 technology. HeLa cells were transfected with 
the CRISPR/Cas9  plasmids  as  described  in Materials  and Methods. Cells  from  different  colonies 
(represented as KO) expanded, treated with hIFNβ for 18 h, lysed, and total proteins were resolved 
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serial dilution onto RK13‐E3 cells. Data are representative of three independent experiments. 
In addition, PKR knockout also enhanced WT‐MYXV progeny titers. When HeLa PKR‐/‐ cells 
were pretreated with uIFNα or hIFNβ and then infected with WT‐MYXV or vMyxM029KO viruses 
at  an MOI  of  0.1 we  observed  that  virus  spread  and  foci  formation was  retarded  (Figure  5A) 
suggesting that IFN‐induced antiviral activity is partially functional against MYXV in human cells 
even  in the absence of PKR. We also measured the formation of progeny virus  in these uIFNα or 
hIFNβ‐treated and MYXV or M029‐minus virus‐infected HeLa PKR‐/‐ cells. As expected, both uIFNα 
and hIFNβ‐induced antiviral  responses  reduced  the  titer of WT‐MYXV  in HeLa PKR‐/‐  cells  like 
parental Hela or GM02504 cell lines. However, under these IFN‐treatment conditions, vMyxM029KO 
virus was unable to produce any progeny virus (Figure 5B). Again, hIFNβ had more potent antiviral 
effects based on the log10 changes in viral titer (Figure 5C). These results confirm that, in human cells, 
Figure 4. CRISPR-mediated PKR knoc t i e cells can rescue vMyxM029KO virus replication.
(A) Generation of PKR knockout cells by CRISPR/CAS9 technology. HeLa cells were transfected
with the CRISPR/Cas9 plasmids as described in Materials and Methods. Cells from different colonies
(represented as KO) expanded, treated with hIFNβ for 18 h, lysed, and total proteins were resolved
by SDS-PAGE and analyzed by Western blotting to detect endogenous PKR, IFN-stimulated gene 15
(ISG15) and actin as a loading control. Colony 2 (KO:2) was selected for further experiments and
labeled as HeLa PKR-/- cells; (B) vMyxM029KO virus is able to replicate in the HeLa PKR-/- colonies.
HeLa ctrl or HeLa PKR-/- colonies were infected with vMyxM029KO virus and fluorescence images
were taken 48 hpi; (C) Single step growth curves of MYXV infection in HeLa ctrl and HeLa PKR-/-
cells. The indicated cells were infected with WT-MYXV or vMyxM029KO at an MOI of 5, and then cells
were collected at 1, 6, 18, 30 and 48 hpi. The virus titers were determined in triplicate following serial
dilution onto RK13-E3 cells. Data are representative of three independent experiments.
In addition, PKR knockout also enhanced WT-MYXV progeny titers. When HeLa PKR-/- cells
were pretreated with uIFNα or hIFNβ and then infected with WT-MYXV or vMyxM029KO viruses at
an MOI of 0.1 we observed that virus spread and foci formation was ret rded (Figure 5A) sugg sting
that IFN-induced antiviral activity i partially functional against MYXV in h man c lls even in the
absence of PKR. We also measured the formation of progeny virus in these uIFNα or hIFNβ-treated and
MYXV or M029-minus virus-infected HeLa PKR-/- cells. As expected, both uIFNα and hIFNβ-induced
antiviral responses reduced the titer of WT-MYXV in HeLa PKR-/- cells like parental Hela or GM02504
cell lines. However, under these IFN-treatment conditions, vMyxM029KO virus was unable to produce
any progeny virus (Figure 5B). Again, hIFNβ had more potent antiviral effects based on the log10
changes in viral titer (Figure 5C). These results confirm that, in human cells, M029 is required to
partially overcome the type I IFN induced antiviral state, but in a manner that is independent of PKR.
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Figure 5. M029 is required for partial inhibition of the type I IFN‐induced antiviral state in human 
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with the WT‐MYXV or vMyxM029KO viruses at an MOI of 0.01 and fluorescence images were taken 
48 hpi; (B) HeLa PKR‐/‐ cells were mock or treated with uIFNα, hIFNβ containing media for 18 h and 
infected with the WT‐MYXV or vMyxM029KO viruses at an MOI of 5.0 and then cells were collected 
at 1 h (adsorption), 24 h and 48 hpi for virus titration. The virus titers were determined in triplicate 
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after 24 h or 48 h infection. ** p < 0.01 *** p < 0.001; (C) Table showing log10 changes in virus titer after 
different type I IFN treatment compare to the untreated samples at 24 h and 48 h in HeLa PKR‐/‐ cells. 
3.5. PKR Knockdown in Rabbit Cells Cannot Rescue vMyxM029KO Virus Replication after Establishment of 
the Type I IFN‐Induced Antiviral State 
Like human and mouse cells, we then tested the role of PKR in the type I IFN‐induced antiviral 
states in rabbit RK13 cells by siRNA‐mediated transient knockdown of PKR. We have confirmed that, 
at least in RK13 cells, type I IFN treatment after PKR knockdown did not further enhance the level of 
PKR protein as assessed using Western blot analysis (Figure 6B). Unlike human and mouse cells, PKR 
knockdown in RK13 cells did not enhance the titer of vMyxM029KO virus significantly as observed 
by foci formation and virus titration (Figure 6A and data not shown). When treated with type I IFN, 
Figure 5. M029 is required for partial inhibition of the type I IFN-induced antiviral state in human
cells; (A) HeLa PKR-/- cells were treated with uIFNα or hIFNβ containing media for 18 h and infected
with the WT-MYXV or vMyxM029KO viruses at an MOI of 0.01 and fluorescence images were taken
48 hpi; (B) HeLa PKR-/- cells were mock or treated with uIFNα, hIFNβ containing media for 18 h and
infected with the WT-MYXV or vMyxM029KO viruses at an MOI of 5.0 and then cells were collected
at 1 h (adsorption), 24 h and 48 hpi for virus titration. The virus titers were determined in triplicate
following serial dilution onto permissive RK13-E3 cells. Statistics are relative to untreated virus titer
after 24 h or 48 h infection. ** p < 0.01 *** p < 0.001; (C) Table showing log10 changes in virus titer after
different type I IFN treatment compare to the untreated samples at 24 h and 48 h in HeLa PKR-/- cells.
3.5. PKR Knockdown in Rabbit Cells Cannot Rescue vMyxM029KO Virus Replication after Establishment of
the Type I IFN-Induced Antiviral State
Like human and mouse cells, we then tested the role of PKR in the type I IFN-induced antiviral
states in rabbit RK13 cells by siRNA-mediated transient knockdown of PKR. We have confirmed that,
at least in RK13 cells, type I IFN treatment after PKR knockdown did not further enhance the level of
PKR protein as assessed using Western blot analysis (Figure 6B). Unlike human and mouse cells, PKR
knockdown in RK13 cells did not enhance the titer of vMyxM029KO virus significantly as observed by
foci formation and virus titration (Figure 6A and data not shown). When treated with type I IFN, the
PKR knockdown RK13 cells were not able to support vMyxM029KO virus replication, like the parental
RK13 cells (Figure 6C). These results again confirm that, like human and mouse cells, PKR in rabbit
cells is not an essential effector target for the inhibition of type I IFN-induced antiviral state by MYXV.
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images  were  taken  48  hpi;  (B)  Western  blot  analysis  of  PKR  knockdown  RK13  cells  to  detect 
endogenous PKR and actin as  loading control; (C) PKR knockdown RK13 cells were  infected with 
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collected 1 h, 24 h and 48 h for titration onto RK13‐E3 cells. Statistics are relative to untreated virus 
titer after 24 h or 48 h infection. ** p < 0.01 *** p < 0.001. 
3.6. Type I IFN‐Induced Antiviral States Inhibit Viral Protein Synthesis in a Highly Species‐Specific Manner 
Our  results  indicate  that  the  type  I  IFN‐induced  antiviral  state  can  compromise  MYXV 
replication,  either  in  the  absence  or  presence  of M029,  at multiple  levels  in  various  cell  types 
originated  from  different  species  outside  the  rabbit.  To monitor  at what  level  the  replication  of   
WT‐MYXV and M029‐minus viruses are affected by IFN pre‐treatment in cells from different species, 
we measured the  level of viral gene expression using recombinant viruses expressing FLuc under 
poxvirus synthetic early/late promoter and monitored the expression of early and late proteins by 
western blot analysis. In all of these experiments, we have only used the species‐specific type I IFNs 
that  showed  the  most  potent  inhibition  against  MYXV  replication.  In  rabbit  RK13  cells,  IFN 
pretreatment and infection with WT‐MYXV caused an initial retardation in the initiation of viral gene 
expression  at  6  h,  but which was  totally  recovered  by  24–48  h  (Figure  7A). On  the  other  hand, 
Figure 6. Knockd wn f PKR cannot rescue M029- i YXV sensitivity to the type I IFN-induced
antiviral state in rabbit RK13 cells. RK13 cells were transiently transfected with siRNAs targeting rabbit
PKR for 48 h before infection with the viruses or treatment with hIFNβ; (A) Control or PKR knockdown
RK13 cells were infected with vMyxM029KO virus at an MOI of 0.01 and fluorescence images were
taken 48 hpi; (B) Western blot analysis of PKR knockdown RK13 cells to detect endogenous PKR and
actin as loading control; (C) PKR knockdown RK13 cells were infected with vMyxM029KO viruses
before or after treatment with IFNβ at an MOI of 5 and then cell were collect d 1 h, 24 h and 48 h for
titration onto RK13-E3 cells. S atistics are relative to untreated virus titer after 24 h or 48 h infection.
** p < 0.01 *** p < 0.001.
3.6. Type I IFN-Induced Antiviral States Inhibit Viral Protein Sy thesis in a Highly Species-Specific Manner
Our results indicate that the type I IFN-induced antiviral state can compromise MYXV replication,
either in the abse ce or presence of M029, at multiple levels in various cell types originat d from
different sp cies outside the rabbit. To monitor at what level he replication of WT-MYXV and
M029-minus viruses are affected by IFN pre-treatment in cells from different species, we measured the
level of viral gene expression using recombinant viruses expressing FLuc under poxvirus synthetic
early/late promoter and monitored the expression of early and late proteins by western blot analysis.
In all of these experiments, we have only used the species-specific type I IFNs that showed the most
potent inhibition against MYXV replication. In rabbit RK13 cells, IFN pretreatment and infection with
WT-MYXV caused an initial retardation in the initiation of viral gene expression at 6 h, but which
was totally recovered by 24–48 h (Figure 7A). On the other hand, vMyxM029KO virus was unable to
rescue viral gene expression even at the later time points of infection in the IFN-treated RK13 cells
(Figure 7A). This suggests that de novo expression of M029 is required for the effective inhibition of
the IFN-induced antiviral state in rabbit cells. When we analyzed early (M-T7) and late (Serp-1) viral
protein synthesis by Western blot analysis in RK13 cells, type I IFN treatment had minimal effect on
late protein synthesis of WT-MYXV, but viral late gene expression was completely lost when infected
with vMyxM029KO virus (Figure 7B).
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Figure 7. Type I IFN‐induced antiviral state can inhibit the expression of MYXV early and late proteins 
in a species‐specific manner;  (A) Rabbit RK13 and  (C) Mouse MEF PKR‐/‐ cells were  treated with 
hIFNβ  and  mIFNβ  containing  media  for  18  h  and  infected  with  vMyx‐FLuc  (WT‐MYXV)  or 
vMyxM029KO‐FLuc viruses for the  indicated time points. Cells were then processed for  luciferase 
assay. Percent  reduction  in FLuc expression was calculated  from  the  samples not pretreated with 
IFNs. The assay was performed in triplicate; (B) Rabbit RK13 cells were treated with mock or hIFNβ 
Figure 7. Type I IFN-induced antiviral state can inhibit the expression of MYXV early and late
proteins in a species-specific manner; (A) Rabbit RK13 and (C) Mouse MEF PKR-/- cells were treated
with hIFNβ and mIFNβ containing media for 18 h and infected with vMyx-FLuc (WT-MYXV) or
vMyxM029KO-FLuc viruses for the indicated time points. Cells were then processed for luciferase
assay. Percent reduction in FLuc expression was calculated from the samples not pretreated with
IFNs. The assay was performed in triplicate; (B) Rabbit RK13 cells were treated with mock or hIFNβ
containing media for 18 h and infected with WT-MYXV or vMyxM029KO viruses and cells were
collected at the indicated time points for Western blot analysis; (D) Mouse MEFs and MEF PKR-/-
cells were treated with mock or mIFNβ containing media for 18 h and infected with WT-MYXV or
vMyxM029KO viruses and cells were collected at he indicated time points for Western blot analysis;
(E) Human HeLa control and (F) HeLa PKR-/- cells were treated with mock (lanes 1-7) or hIFNβ
(lanes 8-14) containing media for 18 h and infected with WT-MYXV or vMyxM029KO viruses and cells
were collected at the indicated time points for Western blot analysis.
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In contrast to RK13 cells, in WT-MEFs (data not shown) or PKR-/- MEF cells, pretreatment with
mIFNβ almost completely blocked viral late gene expression at 6 h and 24 h, which was even more
evident when infected with vMyxM029KO virus (Figure 7C). This was further confirmed by analyzing
early and late protein synthesis by Western blot (Figure 7D). This observation clearly demonstrates that
in MEFs, type I IFN-induced antiviral states block MYXV late protein synthesis even in the absence
of PKR. We also monitored the effect of type I IFN-induced antiviral states on viral gene expression
in HeLa control and HeLa PKR-/- cells using Western blot analysis. In the parental HeLa or HeLa
control cells, replication of vMyxM029KO virus was blocked due to the lack of late gene expression
(Figure 7E). In this cell line, type I IFN treatment significantly reduced both early and late protein
synthesis of WT-MYXV. In the HeLa PKR-/- cell lines, late viral gene expression was rescued for
vMyxM029KO virus infection, but which was completely inhibited by the treatment with type I IFN
(Figure 7F). In contrast, the late gene expression of WT-MYXV was further reduced by type I IFN
even in the absence of PKR. Collectively, these results indicate that M029 is unable to antagonize the
mIFNβ-induced antiviral state in mouse cells, only partially in human cells, but does so very efficiently
in rabbit cells.
3.7. MYXV Does Not Alter the Levels of Pre-Existing Type I IFN-Induced IFN-Stimulated Genes (ISGs) in
Rabbit, Human or Mouse Cells
The next step was to check whether the failure of M029-minus virus to replicate in IFN-treated
rabbit cells, and in PKR-deficient permissive human or mouse cells, can be explained by virus-induced
changes in the levels of ISG proteins. The induction of antiviral ISGs, for example Mx1, ISG15, and
OAS1 in response to IFN treatment was assessed in rabbit, human and mouse cells. Significantly
increased ISG expression levels after IFN treatment were detected in human (HeLa) and mouse (MEF)
cells, however, the upregulation of ISGs were relatively less robust in rabbit (RK13) cells in response
to human or rabbit IFN treatment alone (Figure 8A,B, and not shown). However, transfection of
poly I:C significantly enhanced the levels of induced expression of these ISGs in RK13 cells, which
did not affect the WT-MYXV replication under these conditions (Figure 8C, and not shown). To test
whether these levels of expressed ISGs were altered after WT-MYXV or vMyxM029KO virus infection,
the cells were pre-treated with IFN or transfected with poly I:C (RK13 cells) and then infected with
the test viruses. Measuring the levels of ISG RNAs by qPCR indicate that both the WT-MYXV and
vMyxM029KO viruses were unable to alter the tested ISG mRNA levels in HeLa, MEF or RK13
(or by MYXV and M029KO virus alone) cell lines when the IFN is added prior to the virus. We also
observed that infection with either virus alone did not enhance the transcription of any tested ISGs.
These results suggest that neither WT-MYXV nor M029-minus virus alters the levels of pre-existing
ISG that mediate the antiviral state in IFN pre-treated cells of any of the three species that were tested.
We have also transiently expressed M029 alone in human cells and observed no inhibition in the levels
of IFN-induced expression of tested ISGs (data not shown). In addition, we have not observed any
effects on the IFN-induced expression of selective ISGs at the translational level in HeLa cells (data not
shown). Collectively, these data indicate that the inability of M029-minus MYXV to replicate in human
or mouse cells is not due to any inability to alter pre-expressed ISGs that mediate the antiviral state.
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PKR‐/‐ or MEF PKR‐/‐cells even in the continued presence of type I IFNs starting at 6 h (Figure 9A). 
This was further confirmed by calculating the log10 changes in virus titer, which showed very minimal 
changes in virus titer (Figure 9B). 
These results suggest that M029 is not required for the viral inhibition of type I IFN signaling 
that  establishes  the  antiviral  state.  To  further  confirm  this,  we  checked  the  level  of  STAT‐1 
phosphorylation after treatment with hIFNβ in the absence or presence of MYXV infection of HeLa 
cells. Phosphorylated STAT1  (pSTAT1)  can be detected only  in  the  IFNβ‐treated  cells but not  in   
WT‐MYXV  or  vMyx‐M029KO  infected  cells  (Figure  9C).  Infection  with  either  WT‐MYXV  or 
vMyxM029KO viruses before hIFNβ treatment equivalently reduced the levels of pSTAT1 after 6 h 
Figure 8. MYXV infection does not alter levels of ISGs in IFN pre-treated cells originating from different
species; (A) Human HeLa PKR-/- and (B) Mouse MEF PKR-/- cells were treated with hIFNβ and
mIFNβ respectively for 18h and infected with either WT-MYXV or vMyxM029KO viruses for another
24 h. Total RNA was isolated from the harvested cells and subjected to reverse transcription and
real-time polymerase chain reaction (qPCR) to monitor the expression of ISGs. Fold changes are based
on GAPDH as control; (C) Rabbit RK13 cells were transfected with poly I:C for 18 h and infected with
either WT-MYXV or vMyxM029KO viruses for 24 h and total RNA was isolated from the harvested
cells and subjected to reverse transcription and qPCR to monitor the expression of ISGs. Fold changes
are based on GAPDH as control.
3.8. Can Inhibit Type I IF Signaling ven in the bsence of 029 in ultiple ell Species
e teste et er i fectio rior to t e treat e t of cells it ty e I IF ig t block
s bseq ent ty e I IFN signaling in virus-infected rabbit, human or mouse cells. For this, cells were first
infected with either WT-MYXV or vMyxM029KO viruses with an MOI of 5 for 6 h and then followed
by addition of type I IFN. In these pre-infected cells, the effects of subsequent type I IFN treatment on
virus replication was measured by tittering progeny. Our results indicate that both the WT-MYXV and
vMyxM029KO viruses were able to complete their replication cycles in RK13, HeLa PK -/- or MEF
P -/-cells even in the continued presence of type I IFNs starting at 6 h (Figure 9A). This was further
confirmed by calculating the log10 changes in virus titer, which showed very minimal changes in virus
titer (Figure 9B).
These results suggest that M029 is not required for the viral inhibition of type I IFN signaling that
establishes the antiviral state. To further confirm this, we checked the level of STAT-1 phosphorylation
after treatment with hIFNβ in the absence or presence of MYXV infection of HeLa cells. Phosphorylated
STAT1 (pSTAT1) can be detected only in the IFNβ-treated cells but not in WT-MYXV or vMyx-M029KO
infected cells (Figure 9C). Infection with either WT-MYXV or vMyxM029KO viruses before hIFNβ
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treatment equivalently reduced the levels of pSTAT1 after 6 h of infection, but not at 1 h. This suggests
that M029 is not the viral protein involved in the inhibition of IFN ligand-induced signaling after
MYXV infection.
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Figure 9. MYXV infection is able to inhibit post-infection type I IFN signaling even in the absence of
M029; (A) MEF PKR-/-, RK13 and HeLa PKR-/- cells were infected with WT-MYXV and vMyxM029KO
viruses alone for 1 h (adsorption) and 6 h, after which media containing mIFNβ or hIFNβ (500 U/mL)
were added in one of the sample and harvested after 48 h for virus titration; (B) Table showing log10
changes in virus titer after different type I IFN treatment compare to the untreated samples at 48 h in
MEF PKR-/-, RK13 and HeLa PKR-/- cells; (C) HeLa cells were left untreated, treated with hIFNβ for
30 mn, infected with vMyxGFP and vMyxM029KO viruses alone for 1 h and 6 h or treated with hIFNβ
for 30 m post-infection. The membranes were first probed wit anti-pSTAT1 antibody, stripped and
probed for STAT1 and again strippe and probed for actin (loading control); (D) HeLa PKR-/- cells
were treated with hIFNβ for 18h after mock or infection with vMyxGFP or vMyxM029KO viruses
for 6 h and total RNA was isolated from the cells and subjected to rev rse transcription and qPCR to
monito the expression of Mx1 and ISG15. Fold changes are based on GAPDH as c ntrol; (E) MEF
PKR-/- cells were treated with mIFNβ for 18 h after mock or infection with vMyxGFP for 6 h and
total RNA was isolated from the cells and subjected to reverse transcription and qPCR to monitor th
expression of Mx1 and ISG15. ** p < 0.01 *** p < 0.001. Fold changes are based on GAPDH as contr .
Viruses 2017, 9, 27 17 of 22
To further confirm that WT-MYXV or vMyxM029KO infection prior to the treatment with
type I IFN can block subsequent IFN-induced STAT signaling, we examined the levels of IFN-induced
ISGs in different cell types. Both WT-MYXV and M029-minus virus significantly reduced the level
of IFN-induced expression of ISGs like Mx1 and ISG15 in human and mouse cell lines, as measured
by qPCR (Figure 9 D,E). These results confirm that MYXV infection, even in the absence of M029,
inhibited IFN-induced STAT signaling and thus also the induction of downstream ISGs, provided that
the cells are pre-infected prior to IFN addition.
4. Discussion
In this study we describe the role of the MYXV-encoded dsRNA binding protein M029 in
antagonizing the antiviral state induced by type I IFNs in different species of host cells. This is
of particular interest because, although the natural in vivo tropism of MYXV is strictly for lagomorphs
such as the European rabbit, the virus is also permissive in cultured cells derived from many diverse
non-rabbit species in vitro. Indeed, MYXV replicates productively in many classes of human cancer
cells and is being developed as an oncolytic viro-therapeutic for several diverse human cancers [10,12].
M029 is a pivotal host range protein that is required for MYXV replication in a broad variety of cultured
cell lines originated from diverse species including rabbits, human and mice. We have previously
reported that at least some of the host range functions of M029 are mediated by the inhibition of
PKR activation/phosphorylation in response to virus infection [26]. In all human cells that were
tested, siRNA-mediated knockdown of the expression of PKR at least partially rescued the replication
defect of M029-minus MYXV. We now show that for both human and mouse cells, the replication of
M029-minus virus can be rescued in part by genetic knockout of PKR in these cells. These observations
suggest that the host range tropism function of M029 is mediated in part by the inhibition of PKR
activation in a relatively species-independent manner. We also report that, although PKR inhibition is
critical for MYXV tropism in transformed/immortalized human or mouse cells, important additional
antiviral functions of M029 are mediated independently of PKR and this latter activity of M029 is
remarkably species specific. Specifically, we show that MYXV exploits M029 to achieve close to total
nullification of the type I IFN induced antiviral state in rabbit cells, but this IFN blockade is only partial
against the antiviral state established in human cells and is nearly nonexistent against the antiviral
state in mouse cells.
Type I IFNs play a major role in inducing innate antiviral responses that protect primary cells
and tissues from virus infection. To establish successful infection in their hosts, many viruses are able
to antagonize one or more aspects of the type I IFN-induced antiviral responses. MYXV is a rabbit
specific poxvirus and inhibits rabbit type I IFN induced responses as part of its genetic program that
mediates pathogenesis in the European rabbit host. However, at the molecular level, how MYXV
neutralizes the type I IFN pathway and subsequent IFN-induced antiviral state remains to be clarified.
MYXV lacks an obvious encoded type I IFN receptor homolog, such as the secreted B18 IFN antagonist
in VACV [34]. Although the MYXV ORF 135 is a related family member to other poxviral homologs of
the IFN receptor, subsequent studies failed to demonstrate any anti-IFN activities of M135 in rabbits or
in rabbit cells [31]. Later studies using rabbit RK13 cells demonstrated that MYXV is indeed able to
effectively inhibit rabbit IFN responses, which suggested that MYXV likely encodes protein(s) that are
able to inhibit IFN signaling and/or the IFN-induced antiviral state. We now demonstrate that the
ability of MYXV to inhibit type I IFN responses in rabbit cells is either compromised or completely lost
when the virus infects human or mouse cells possessing IFN-response competency.
In rabbit RK13 cells, M029-minus MYXV can still replicate and produce infectious progeny
following high multiplicity infection, but the foci size after low multiplicity infection was smaller
compare to the WT-MYXV infection [26]. This is partly because MYXV-encoded protein M156, a
homologue of VACV K3, can inhibit rabbit PKR in RK13 cells [35]. However, we now show that type I
IFN pretreatment of RK13 cells and induction of the antiviral state completely inhibited late MYXV
protein synthesis in the absence of M029, which then prevented the formation of progeny. However,
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the M029-minus MYXV was still able to inhibit the IFN signaling induced by exogenous IFN ligand
added 6 hpi even in the absence of M029. This suggests that other protein(s) independent of M029
from MYXV are involved in the blockade of IFN-induced JAK/STAT signaling. Interestingly, unlike
WT-MYXV, M029-minus virus could not spread efficiently to neighboring uninfected RK13 cells and
form foci, thus further confirming that M029 is required for antagonizing the induced antiviral state in
rabbit cells.
MYXV is able to successfully replicate in some cultured human cells, such as human primary
fibroblasts, as long as the infected cells do not induce IFN and/or TNF as a consequence of the virus
infection. Thus, MYXV is non-permissive in primary human macrophages because the virus infection
co-induces both IFN and TNF, that rapidly renders cells in the culture (including even admixed
“permissive” human fibroblasts) non-permissive for the virus in a paracrine fashion. However, unlike
rabbit cells, where the viral inhibition of IFN pathways is very successful, MYXV is able to only
partially antagonize the human type I IFN induced antiviral state [6,36]. Here we show that the ability
of MYXV to replicate in human cells is compromised in the presence of type I IFN, provided the cells
can respond to IFN, but this partial inhibition is totally lost in the absence of M029. This suggests
that M029 has retained the ability to partially antagonize the IFN-induced antiviral state in human
cells, albeit with much less efficiency than in rabbit cells. Interestingly, even in the presence of M029,
MYXV is not able to spread and infect neighboring human cells when the cells are pretreated with
IFN. Furthermore, in human cells, viral gene expression analysis suggests that although IFN-induced
activities severely compromise viral gene expression, there was still detectable expression of some late
viral proteins, which subsequently allowed lower but still detectable levels of progeny virus formation.
However, as found in rabbit cells, MYXV is also able to efficiently inhibit IFN signaling in human
cells as long as the virus infection is established prior to the addition of IFNs. Our current and
previous results revealed that MYXV infection caused dephosphorylation of Type I IFN signaling
proteins STAT1 and Tyk2 in human cells [36]. These observations suggested that a viral phosphatase
may be involved in the dephosphorylation of these IFN signaling molecules. In VACV, the viral
phosphatase VH1 is delivered by the input virions, which causes a rapid dose dependent inhibition of
either the type I or type II IFN signal transduction [37,38]. Since we did not observe any substantial
decrease in the phosphorylation of STAT1 after 1 h infection with either WT-MYXV or M029-minus
viruses, but inhibition of STAT1 activation is robust by 6 hpi, this suggests that for MYXV the viral
phosphatase may not be encapsidated within the virion. Since we observed significant decrease
in phosphorylation of STAT1 and expression of downstream ISGs after 6 h of infection with either
WT-MYXV or the M029-knockout virus, this suggests that inhibition of IFN signaling in MYXV-infected
cells also blocked the expression of ISGs and their possible antiviral effects in these infected cells.
Outside the rabbit, MYXV modulation of the type I IFN pathway is highly dependent on the
infected cell type. In primary MEFs, MYXV infection is rapidly sensed and induces the activation of
IFN signaling pathway via phosphorylation of the mitogen-activated protein kinase ERK1/2, which
induces type I IFN and thus inhibits the further replication of MYXV [7]. However, when the MEFs are
immortalized, even after as few as 10 passages in culture (iMEFs), MYXV is now able to productively
infect the cells and produce progeny [8]. This suggests that as the MEFs are immortalized they lose
their innate ability to sense MYXV and no longer induce IFN in response to the infection, although
the cells still possess functionally intact IFN signaling pathways (and still become non-permissive to
MYXV following addition of exogeneous IFN). Thus, the mouse type I IFN-induced antiviral state
still totally inhibits WT-MYXV replication in MEFs, unlike rabbit cells. The replication of M029-minus
virus in iMEFs can be rescued only after PKR knockdown or knockout, however this absence of
PKR is still not sufficient to antagonize the IFN-induced antiviral state against either WT-MYXV or
vMyxM029KO viruses. Our results clearly indicate that the MYXV proteins involved in circumventing
the antiviral state are operationally nonfunctional in mouse cells and only partially functional in
human cells. Interestingly, even in MEFs or MEF PKR-/-, MYXV or M029-minus virus infection can
still efficiently inhibit mouse type I IFN-induced signaling provided the IFN is added at least 6 h after
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the viral infection, suggesting that the induced viral protein(s) are involved in blocking IFN signaling
downstream of the IFN receptor. The most likely candidate is the viral dual specificity phosphatase,
encoded by M069, which operates in a species independent manner.
This is a first study showing that a viral dsRNA binding protein can mediate antiviral functions
in cells from multiple species, but exhibits only strict species-specific inhibition of the IFN-induced
antiviral state (in this case, fully in rabbit cells, partially in human cells, and not at all in mouse
cells). In contrast, MYXV is able to inhibit IFN signaling in a species-independent manner following
virus infection of cells, even in the absence of a soluble decoy receptor for type I IFN, but is highly
species-specific in its ability to antagonize the pre-existing antiviral state.
The prototypic poxvirus VACV antagonize type I IFN activities at both the extracellular and
intracellular levels. VACV type I IFN secreted binding protein B18 competes for IFN binding and
activating of host cellular IFNRs [34]. Other VACV intracellular proteins that modulate IFN signaling
or specific IFN activities include VH1, E3, K3, K1, C6 and C7 [19,37–40]. To date, no known functional
counterpart of the secreted B18 IFN antagonist has been identified in MYXV that inhibits extracellular
rabbit IFN. But relatives of some of the other intracellular VACV anti-IFN effectors, like VH1, E3,
K3 and C7, are indeed encoded by MYXV. This paper presents the first report of a MYXV-encoded
intracellular modulator of IFN activities, M029, which functions to coordinately modulate several host
response pathways, some of which are highly rabbit-specific, whereas others are independent of the
host species. Reports indicate that VACV E3 inhibits IFN-induced responses by inhibiting PKR and
also by directly targeting ISG15, which is induced by type I IFN. Our results indicate that M029 also
inhibits IFN activities by targeting functions of at least some ISGs, however, unlike E3, M029 inhibits
the IFN-induced antiviral state independently of PKR. In our observations, even the WT-MYXV is
unable to alter the pre-induced expression levels of ISGs in all the cell types that we have tested,
provided the antiviral state is established prior to virus infection. Furthermore, transient expression
of M029 alone did not block either the transcription or translation of any tested ISGs. Instead, M029
targets not only ISG effector functions responsible for the antiviral state but also intrinsic antiviral
factors that are constitutively present and otherwise inhibit MYXV replication in non-rabbit cells in the
absence of M029 (data not shown). Instead, MYXV gene products, of which M029 is a major player,
can completely overcome the IFN-induced antiviral state in rabbit cells, but only partially in human
cells, and not at all in mouse cells. In human cancer cells that have undergone multiple defects in
their capacity to mount antiviral defense pathways, there is an even further transition away from the
primary human cell sensitivity to IFN to a more “rabbit-like” phenotype that is more susceptible to
infection by MYXV.
IFN induces the expression of hundreds of ISGs in all mammalian cells, but it is not known
how many of these actually possess operational antiviral functions against poxviruses like MYXV,
nor how these antiviral activities compare between species. At this point it is difficult to define how
many host ISGs are actually targeted by M029. It is clear that host PKR is targeted for inhibition by
M029 to mediate tropism in mammalian cells from many species but M029 also plays a key role in
the inhibition of the antiviral state induced by IFN in rabbit cells, a partial inhibitory role in human
cells, and essentially no inhibitory role in mouse cells. The M029KO virus remains sensitive to type
I IFN-induced responses even in the absence of PKR, suggesting that other cellular ISG proteins are
also targeted for inhibition of the IFN-induced antiviral state, which is probably linked with the host
specific modulatory functions of these members of the E3 family of RNA binding proteins. Thus,
replacing any one viral dsRNA binding protein with even a related orthologue from a different virus
may rescue the in vitro replication functions in certain cultured cells but not necessarily restore full
in vivo pathogenesis.
Our results also indicate that MYXV is able to inhibit type I IFN signaling in most cell types, once
the cell is infected and has had sufficient time to express its repertoire of early immunoregulatory
proteins. However, MYXV is severely defective at neutralizing a pre-existing IFN-induced antiviral
state in cells outside of the rabbit species, which indicates that many of the viral immune-inhibitory
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molecules are more adapted for the rabbit species-specific inhibition of type I IFN. Like VACV, MYXV
almost assuredly encodes additional proteins that function in the inhibition of the IFN antiviral state,
in addition to M029. Further knowledge about how MYXV manipulates IFN pathways in human cells,
in particular for primary vs transformed cells, will help further the development of MYXV as oncolytic
virus for the treatment of human cancers. These studies will also enhance our knowledge about viral
tropism at the cellular and host level, not only in evolutionary hosts, but also when a virus occasionally
makes a species leap into a new host.
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